SIEGE: Scheduling nab-paclitaxel with Gemcitabine (SIEGE)

  • Clinical Trials
  • London

Website Pancreatic Cancer UK

UK Clinical Trials, clinical research london

Why is this trial being carried out?
Gemcitabine is a chemotherapy drug that is often used to treat pancreatic cancer. It is sometimes combined with other drugs to try to improve treatment. One of the drugs it has been combined with is nab-paclitaxel (Abraxane)

This trial is looking at whether giving the gemcitabine and nab-paclitaxel (Abraxane) on two different days in a week (called “sequential” treatment) is a more effective treatment than scheduling them for the same day (called “concomitant” treatment). For the sequential treatment the nab-paclitaxel is given 24 hours before the gemcitabine. The study will also look at the side effects of this combined treatment.

Who is the trial suitable for?
The trial is suitable for patients with metastatic pancreatic cancer (cancer that has spread to another part of the body) and who have not had previous chemotherapy for metastatic disease. Your doctor(s) will explain these and any other requirements to join the trial.

Trial centres
Addenbrooke’s Hospital, Cambridge
Leicester Royal Infirmary
Bristol Haematology & Oncology Centre
Royal Free Hospital, London
The Christie Hospital, Manchester
Clatterbridge Centre for Oncology
Royal Surrey County Hospital, Guildford
Royal Cornwall Hospital, Truro
Queen Elizabeth Hospital Birmingham
Western General Hospital, Edinburgh
Colchester Hospital University NHS Foundation Trust
Hammersmith Hospital, London
Recruitment start date: January 2014

This trial is currently not recruiting, but it hopes to start recruiting more people soon.

Study end date: December  2015

 

To apply for this job email your details to enquiries@pancreaticcancer.org.uk